A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology (ICAN)

AstraZeneca

Status: Completed

Conditions: Non-Small Cell Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01106781

NIS-OCN-DUM-2009/1

Details and patient eligibility

About

This is a descriptive observational study. The primary objective is to explore the EGFR gene mutation status in early stage NSCLC with adenocarcinoma histology after complete resection. The patients should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation in regular medical practice.

Enrollment: 591 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histological diagnosed as adenocarcinoma type of non-small cell lung cancer
• Have completed lung cancer operation
• The tumour EGFR gene mutation status test was performed as regular medical practice

Exclusion criteria

• Patients who disagree to participate this study

Trial design

591 participants in 1 patient group

1

Description:

Patients in this group should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation.